Four Chinese patent medicines for regulating stomach for functional dyspepsia: a rapid health technology assessment.
10.19540/j.cnki.cjcmm.20220520.501
- Author:
Si-Min XU
1
;
Ze-Qi DAI
1
;
Xue WU
1
;
Miao-Miao LI
2
;
Xing LIAO
1
Author Information
1. Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences Beijing 100700, China.
2. Institute of Basic Theory for Chinese Medicine,China Academy of Chinese Medical Sciences Beijing 100700, China.
- Publication Type:Systematic Review
- Keywords:
Biling Weitong Granules;
Dalitong Granules;
Qizhi Weitong Granules(Tablets/Capsules);
Zhizhu Kuanzhong Capsules;
functional dyspepsia;
rapid health technology assessment
- MeSH:
Capsules;
China;
Chlorobenzenes;
Domperidone/therapeutic use*;
Drugs, Chinese Herbal/therapeutic use*;
Dyspepsia/drug therapy*;
Humans;
Nonprescription Drugs/therapeutic use*;
Stomach;
Sulfides;
Tablets;
Technology Assessment, Biomedical
- From:
China Journal of Chinese Materia Medica
2022;47(17):4778-4788
- CountryChina
- Language:Chinese
-
Abstract:
This study evaluated and compared the efficacy, safety and economy of four Chinese patent medicines(CPMs) in the treatment of functional dyspepsia(FD) using the method of rapid health technology assessment. It aims to provide decision-makers with rapid decision-making information. The eight Chinese and English databases were comprehensively and systematically searched for the relevant clinical research. Studies were screened and evaluated. A total of 110 studies were identified, including 95 randomized controlled trials(RCTs), 7 controlled clinical trials(CCTs), 7 systematic review/Meta-analysis and 1 economic evaluation, among which 28 were Dalitong Granules, 49 were Zhizhu Kuanzhong Capsules, 3 were Biling Weitong Granules and 30 were Qizhi Weitong Granules(Tablets/Capsules). The quality of the included literature was generally low. The efficacy of four CPMs alone or combined with western medicine in the treatment of FD is different. Dalitong Granules was used to treat motility disorder in FD. Zhizhu Kuanzhong Capsules and Qizhi Weitong Granules(Tablets/Capsules) can treat FD patients with anxiety and depression. Qizhi Weitong Granules(Tablets/Capsules) were mainly used in FD for perimenopausal patients. There were no serious adverse reactions in the clinical study of four CPMs in the treatment of FD. Dalitong Granules has better effects than mosapride in the treatment of FD, but the cost is slightly higher. The cost-effectiveness ratio of Zhizhu Kuanzhong Capsules in the treatment of FD patients with anxiety and depression was lower than that of Domperidone. In terms of average daily price, Qizhi Weitong Tablets has the highest price(27.00 yuan per day), Qizhi Weitong Granules has the lowest price(5.04 yuan per day), Biling Weitong Granules has a relatively high price(15.53 yuan per day), followed by Dalitong Granules(13.03 yuan per day). The evidence of Dalitong Granules covered the efficacy, safety and economy, which is relatively complete compared with the other three drugs. It has effective potential in the treatment of motility disorder in FD. Further research in this field in the future is needed.
